Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Norway.
The KG Jebsen Centre for Cancer Immunotherapy, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Cancer Immunol Res. 2018 Apr;6(4):467-480. doi: 10.1158/2326-6066.CIR-17-0207. Epub 2018 Feb 19.
Natural killer (NK) cells hold potential as a source of allogeneic cytotoxic effector cells for chimeric antigen receptor (CAR)-mediated therapies. Here, we explored the feasibility of transfecting CAR-encoding mRNA into primary NK cells and investigated how the intrinsic potential of discrete NK-cell subsets affects retargeting efficiency. After screening five second- and third-generation anti-CD19 CAR constructs with different signaling domains and spacer regions, a third-generation CAR with the CH2-domain removed was selected based on its expression and functional profiles. Kinetics experiments revealed that CAR expression was optimal after 3 days of IL15 stimulation prior to transfection, consistently achieving over 80% expression. CAR-engineered NK cells acquired increased degranulation toward CD19 targets, and maintained their intrinsic degranulation response toward CD19 K562 cells. The response of redirected NK-cell subsets against CD19 targets was dependent on their intrinsic thresholds for activation determined through both differentiation and education by killer cell immunoglobulin-like receptors (KIR) and/or CD94/NKG2A binding to self HLA class I and HLA-E, respectively. Redirected primary NK cells were insensitive to inhibition through NKG2A/HLA-E interactions but remained sensitive to inhibition through KIR depending on the amount of HLA class I expressed on target cells. Adaptive NK cells, expressing NKG2C, CD57, and self-HLA-specific KIR(s), displayed superior ability to kill CD19, HLA low, or mismatched tumor cells. These findings support the feasibility of primary allogeneic NK cells for CAR engineering and highlight a need to consider NK-cell diversity when optimizing efficacy of cancer immunotherapies based on CAR-expressing NK cells. .
自然杀伤 (NK) 细胞有望成为嵌合抗原受体 (CAR) 介导疗法中同种异体细胞毒性效应细胞的来源。在这里,我们探索了将 CAR 编码 mRNA 转染到原代 NK 细胞中的可行性,并研究了离散 NK 细胞亚群的固有潜力如何影响重定向效率。在筛选了五种具有不同信号结构域和间隔区的第二代和第三代抗 CD19 CAR 构建体后,根据其表达和功能谱选择了一种去除 CH2 结构域的第三代 CAR。动力学实验表明,在转染前通过 IL15 刺激 3 天可获得最佳的 CAR 表达,始终实现超过 80%的表达。CAR 工程化的 NK 细胞对 CD19 靶标表现出增强的脱颗粒作用,并且保持对 CD19 K562 细胞的固有脱颗粒反应。重定向 NK 细胞亚群对 CD19 靶标的反应取决于通过杀手细胞免疫球蛋白样受体 (KIR) 和/或 CD94/NKG2A 分别与自身 HLA Ⅰ类和 HLA-E 的结合对激活的内在阈值的分化和教育来确定。重定向的原代 NK 细胞对通过 NKG2A/HLA-E 相互作用的抑制不敏感,但仍然对通过 KIR 的抑制敏感,具体取决于靶细胞上表达的 HLA Ⅰ类的量。表达 NKG2C、CD57 和自身 HLA 特异性 KIR(s) 的适应性 NK 细胞显示出杀死 CD19、HLA 低或错配肿瘤细胞的优异能力。这些发现支持了对 CAR 工程化的原代同种异体 NK 细胞的可行性,并强调了在基于表达 CAR 的 NK 细胞的癌症免疫疗法中优化疗效时需要考虑 NK 细胞多样性。